Treatment outcomes in pediatric lymphoma have improved substantially over the past 2 decades; however, the prognosis for patients with high risk or relapsed disease remains poor. We evaluated outcomes of high-dose chemotherapy (HDC) and autologous stem cell transplantation (auto-SCT) in 56 pediatric lymphoma patients. Patients received nitrosourea (51 BCNU; 5 ACNU), etoposide, and cyclophosphamide (BEC; AEC). Median age at HDC/auto-SCT was 12 years (range 2-17 years). Forty-four patients underwent HDC/auto-SCT because they did not achieve complete remission after induction chemotherapy. Eight patients showed relapse and four NK/T-cell lymphoma patients also underwent HDC/auto-SCT. BCNU pneumonitis was diagnosed in nine (16.0%) patients. Eight (14.3%) relapsed after HDC/auto-SCT. Treatment-related mortality occurred in three cases. Five-year event-free survival and overall survival rates were 74.8% [72.7% non-Hodgkin's lymphoma (NHL); 83.3% Hodgkin's disease (HD); 72.7%] and 83.6% (81.6% NHL; 91.7% HD), respectively. HDC/auto-SCT with BEC or AEC regimen for pediatric high-risk lymphoma patients showed feasible outcomes. However, treatment modifications are warranted to reduce relapse and toxicity.

中文翻译：

---

亚硝基脲、依托泊苷和环磷酰胺继以自体干细胞移植治疗儿科淋巴瘤患者。

在过去的 20 年里，小儿淋巴瘤的治疗结果有了显着改善；然而，高危或复发性疾病患者的预后仍然很差。我们评估了 56 名小儿淋巴瘤患者的大剂量化疗 (HDC) 和自体干细胞移植 (auto-SCT) 的结果。患者接受亚硝基脲（51 BCNU；5 ACNU）、依托泊苷和环磷酰胺（BEC；AEC）。HDC/auto-SCT 的中位年龄为 12 岁（范围 2-17 岁）。44 名患者接受了 HDC/auto-SCT，因为他们在诱导化疗后未达到完全缓解。8 名患者出现复发，4 名 NK/T 细胞淋巴瘤患者也接受了 HDC/auto-SCT。9 名 (16.0%) 患者被诊断为 BCNU 肺炎。HDC/auto-SCT 后 8 例 (14.3%) 复发。3 例发生了与治疗相关的死亡。五年无事件生存率和总生存率为 74.8% [72.7% 非霍奇金淋巴瘤 (NHL)；83.3% 霍奇金病（HD）；72.7%] 和 83.6%（81.6% NHL；91.7% HD）。HDC/auto-SCT 与 BEC 或 AEC 方案对儿科高危淋巴瘤患者显示出可行的结果。然而，有必要调整治疗以减少复发和毒性。